ClinicalTrials.gg
CompletedNCT03820726Updated Sep 13, 2023Results posted

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

A Phase 3 interventional study of Nintedanib in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 121 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
3rd of 11
435 · median 81
Started
2019
with 1 other
Phase 3
8 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
6 of 11
Boehringer Ingelheim

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 3rd registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients who completed the INBUILD® trial as planned and who did not prematurely discontinue blinded treatment.
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  • Women of (WOCBP)1 must continue to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method, for 28 days prior to and 3 months after nintedanib administration. A list of contraception methods meeting these criteria is provided in the patient information

Exclusion criteria

Exclusion Criteria:

  • Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of the INBUILD® trial. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in INBUILD®, if the investigator's benefit-risk assessment remains favourable.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Patient not compliant in parent trial (INBUILD®), with trial medication or trial visits, according to investigator's judgement.
  • Previous enrolment in this trial. Further exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    Nintedanib

    Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.

    Drug: Nintedanib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events

    Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.

07

Results

Posted Sep 13, 2023

Participant flow

A phase III, open label, extension trial. The study aimed to evaluate the long-term tolerability and safety of oral nintedanib treatment in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have completed (and did not prematurely discontinue trial medication in) the phase III parent trial, 1199.247 (INBUILD®) NCT02999178.

Participant flow — Overall Study
MilestoneNintedanib
Started435
Treated434
Completed224
Not completed211
Withdrew: Other than listed23
Withdrew: Withdrawal by subject37
Withdrew: Lost to follow-up3
Withdrew: Protocol deviation1
Withdrew: Adverse event146
Withdrew: Not treated1

Outcome measures

PrimaryNumber of Participants With Any Adverse Events

Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events
ParticipantsNintedanib
Number of Participants With Any Adverse Events417

Adverse events

Collected over From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib83/434 (19.1%)234/434 (53.9%)371/434 (85.5%)
Most frequent serious events
Showing 10 of 195
Most frequent serious events
EventNintedanib
PneumoniaInfections and infestations36/434
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders35/434
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders20/434
Respiratory failureRespiratory, thoracic and mediastinal disorders17/434
Acute respiratory failureRespiratory, thoracic and mediastinal disorders15/434
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders14/434
COVID-19Infections and infestations12/434
DyspnoeaRespiratory, thoracic and mediastinal disorders12/434
PneumothoraxRespiratory, thoracic and mediastinal disorders9/434
Atrial fibrillationCardiac disorders7/434
Most frequent other events
Showing 10 of 23
Most frequent other events
EventNintedanib
DiarrhoeaGastrointestinal disorders256/434
NauseaGastrointestinal disorders75/434
CoughRespiratory, thoracic and mediastinal disorders73/434
Weight decreasedInvestigations69/434
DyspnoeaRespiratory, thoracic and mediastinal disorders61/434
VomitingGastrointestinal disorders54/434
BronchitisInfections and infestations48/434
Decreased appetiteMetabolism and nutrition disorders45/434
Alanine aminotransferase increasedInvestigations43/434
NasopharyngitisInfections and infestations38/434

Baseline characteristics

Treated Set (TS): This set included all patients who were dispensed trial medication (nintedanib) and were documented to have taken at least 1 dose of open-label trial medication (nintedanib).

Age, Continuous
Age, Continuous(Years)Nintedanib
Mean65.9 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib
Female211
Male223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nintedanib
Hispanic or Latino65
Not Hispanic or Latino328
Unknown or Not Reported41
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib
American Indian or Alaska Native0
Asian108
Native Hawaiian or Other Pacific Islander1
Black or African American4
White279
More than one race1
Unknown or Not Reported41
08

Study locations

121 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Pulmonary and Sleep of Tampa Bay
    Brandon, Florida 33511, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • Pulmonary and Critical Care Associates of Baltimore
    Towson, Maryland 21286, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Creighton University
    Omaha, Nebraska 68124, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • NewYork-Presbyterian/Weill Cornell Medical Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Medical Arts and Research Center (MARC)
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
  • Centro Dr. Lazaro Langer S.R.L
    Alberdi Sur, X5003DCE, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    C.a.b.a, 1056, Argentina
  • CEMER-Centro Medico De Enfermedades Respiratorias
    Florida, B1602DQD, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Instituto Médico de la Fundación Estudios Clínicos
    Rosario, S2000DEJ, Argentina
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 0N2, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • Hospital Clínico Reg. de Concepción "Dr. G. Grant Benavente"
    Concepción, 4070038, Chile
  • Instituto Nacional del Tórax
    Providencia, Santiago De Chile, 7500691, Chile
  • Centro de Investigación del Maule
    Talca, 3465586, Chile
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • The First Hospital of China Medical University
    Shenyang, 110001, China
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP Louis Pradel
    Bron, 69677, France
  • HOP Côte de Nacre
    Caen, 14033, France
  • CHRU Lille
    Lille, 59037, France
  • HOP Nord
    Marseille, 13915, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Pasteur
    Nice, 06001, France
  • HOP Bichat
    Paris, 75018, France
  • HOP Maison Blanche
    Reims, 51092, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • HOP Civil
    Strasbourg, 67091, France
  • HOP Bretonneau
    Tours, 37044, France
  • Universitätsklinikum Bonn AöR
    Bonn, 53105, Germany
  • Fachkrankenhaus Coswig GmbH
    Coswig, 01640, Germany
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Petrus-Krankenhaus
    Wuppertal, 42283, Germany
  • A.O.U. Policlinico Vittorio Emanuele
    Catania, 95124, Italy
  • Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli
    Forli', 47121, Italy
  • Azienda Ospedaliera Policlinico di Modena
    Modena, 41100, Italy
  • A.O. San Gerardo di Monza
    Monza, 20052, Italy
  • Poli Univ A. Gemelli
    Roma, 00168, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Tosei General Hospital
    Aichi, Seto, 489-8642, Japan
  • Kurume University Hospital
    Fukuoka, Kurume, 830-0011, Japan
  • Sapporo Medical University Hospital
    Hokkaido, Sapporo, 060-8543, Japan
  • National Hospital Organization Himeji Medical Center
    Hyogo, Himeji, 670-8520, Japan
  • Kobe City Medical Center General Hospital
    Hyogo, Kobe, 650-0047, Japan
  • Ibarakihigashi National Hospial
    Ibaraki, Naka-gun, 319-1113, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Kanagawa, Yokohama, 236-0051, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto, Kumamoto, 861-4193, Japan
  • Tohoku University Hospital
    Miyagi, Sendai, 980-8574, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Osaka, Sakai, 591-8555, Japan
  • Osaka Medical College Hospital
    Osaka, Takatsuki, 569-8686, Japan
  • Hamamatsu University Hospital
    Shizuoka, Hamamatsu, 431-3192, Japan
  • Tokushima University Hospital
    Tokushima, Tokushima, 770-8503, Japan
  • Tokyo Medical and Dental University Hospital
    Tokyo, Bunkyo-ku, 113-8519, Japan
  • Toranomon Hospital
    Tokyo, Minato-ku, 105-8470, Japan
  • JR Tokyo General Hospital
    Tokyo, Shibuya-ku, 151-8528, Japan
  • Center Hospital of the National Center for Global Health and Medicine
    Tokyo, Shinjuku-ku, 162-8655, Japan
  • The Catholic University of Korea, Bucheon St.Mary's Hospital
    Bucheon, 14647, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, 13620, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • University Clinical Center, Gdansk
    Gdansk, 80-214, Poland
  • Leszek Giec Upper-Silesian Med.Cent.Silesian Med.Univ.
    Katowice, 40-752, Poland
  • Norbert Barlicki University Clinical Hospital No.1, Lodz
    Lodz, 90-153, Poland

Showing the first 100 of 121 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame frame' are fulfilled , researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2022, 40 months.

Results were first posted in Sep 2023, 1 year after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Jan 29, 2019
StartActual
Apr 16, 2019
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03820726
Responsible party
Sponsor
First posted
Jan 29, 2019
Start date
Apr 16, 2019
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion